Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients

Data regarding the safety and efficacy of COVID-10 vaccines among cancer patients are lacking. Factors such as age, underlying disease and antineoplastic treatment confer negatively to the immune response due to vaccination. The degree of immunosuppression though may be lessen by targeted treatments...

Descripción completa

Detalles Bibliográficos
Autores principales: Liontos, Michalis, Terpos, Evangelos, Kunadis, Elena, Zagouri, Flora, Briasoulis, Alexandros, Skafida, Efi, Fiste, Oraianthi, Markellos, Christos, Andrikopoulou, Angeliki, Gumeni, Sentiljana, Kaparelou, Maria, Koutsoukos, Konstantinos, Gavriatopoulou, Maria, Kastritis, Efstathios, Trougakos, Ioannis P., Dimopoulos, Meletios- Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501917/
https://www.ncbi.nlm.nih.gov/pubmed/34628475
http://dx.doi.org/10.1038/s41391-021-00455-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501917/
https://www.ncbi.nlm.nih.gov/pubmed/34628475
http://dx.doi.org/10.1038/s41391-021-00455-9

Ejemplares similares